UPDATE: B. Riley FBR Maintains Outperform On The Medicines Co., Raises Target To $95 To Reflect Firm's 'heightened conviction in inclisiran taking a dominant market share in the anti-PCSK9 marketplace following strong ORION-11/10/9 Ph. III results'